The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


40 milligram(s) Film-coated tablet

Ipsen PharmaEU/1/16/1136/003-004

Main Information

Trade NameCabometyx
Active SubstancesCabozantinib
Strength40 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderIpsen Pharma
Licence NumberEU/1/16/1136/003-004

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE26 Protein kinase inhibitors


Licence Issued09/09/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back